行情

CTMX

CTMX

CytomX医疗
NASDAQ

实时行情|Nasdaq Last Sale

7.72
+0.12
+1.51%
交易中 11:03 01/29 EST
开盘
7.58
昨收
7.60
最高
7.77
最低
7.53
成交量
7.11万
成交额
--
52周最高
19.75
52周最低
5.10
市值
3.51亿
市盈率(TTM)
-3.5249
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CTMX 新闻

  • 美股盘前:联储利率决议在即 美股三大股指期货普涨
  • 新浪美股.2小时前
  • 万事达2019年净利同比增长近四成 每股收益好于预期
  • 智通财经网.2小时前
  • 美联储决议终极前瞻:两大重要看点值得细究
  • 汇通网.3小时前
  • 波音Q4营收179亿美元低于预期 全年亏损6.36亿美元
  • 新浪财经.3小时前

更多

所属板块

生物技术和医学研究
+0.11%
制药与医学研究
+0.39%

热门股票

名称
价格
涨跌幅

CTMX 简况

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
展开

Webull提供CytomX Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。